- Home
- Reports
- Medical Device
- Facial Paralysis Market
Facial Paralysis Market Information: By Type (Bell’s Palsy, Ramsay Hunt Syndrome), by Diagnosis (Electromyography, Computerized Tomography), by Treatment (Medications, Physical Therapy), End-User (Hospitals, Specialty Centers) – Global Forecast Till 2023
ID: MRFR/MED/4486-HCR | February 2021 | Region: Global | 100 pages
Market Scenario
Facial paralysis is a restriction of the facial movement due to nerve damage. Facial nerve paralysis is characterized by unilateral facial weakness. Some other symptoms include loss of taste, hyperacusis, and decreased salivation and tear secretion.
The global facial paralysis market is majorly driven by the high prevalence of cardiovascular diseases, the launch of technologically advanced devices, increasing inflammation rates, increasing rate of strokes, and growing penetration by market players. Additionally, factors such as the increasing approvals for facial paralysis, government initiatives and support, and rising reimbursement coverage for cardiologic anomalies are likely to drive the market.
Factors that are likely to hamper the growth of the market are product failures and recalls.
Global Facial Paralysis market is expected to grow at a CAGR of 6.5% during the forecast period.
Figure: Global Facial Paralysis Market, by Region, 2017 (%)
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis
Segments
The global facial paralysis market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the market is segmented into bell’s palsy, Ramsay Hunt syndrome, and Lyme disease.
On the basis of diagnosis, the market is segmented into electromyography, computerized tomography, and magnetic resonance imaging.
On the basis of treatment, the market is segmented into medications, physical therapy,
On the basis of medications, the market is further sub-segmented into corticosteroids and antiviral drugs.
On the basis of end-user, the market is segmented into hospitals and clinics, specialty centers, and research centers.
Intended Audience
Pharmaceutical Manufacturers and Suppliers
Medical Research Laboratories
Research and Development (R&D) Companies
Market Research and Consulting Service Providers
Potential Investors
Research Methodology
Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation and market research future analysis
Regional Analysis
The North American facial paralysis market is a growing market in the Americas region. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. The increasing cardiovascular rate is likely to enhance the growth of facial paralysis. Additionally, the increasing demand for minimally invasive procedures, rising government support, and rising demand for technologically advanced treatments are likely to enhance the growth of the facial paralysis market in North America. For instance, according to the American Heart Association, 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, in 2015, around USD 3.2 trillion were spend in healthcare expenditure in the U.S according to the Center for Disease Control and Prevention.
Europe is the second largest market and holds a healthy share in the global facial paralysis market. The European market is expected to grow a during the forecast period owing to the availability of advanced treatment facilities and healthcare expenditure along with growing need for better healthcare infrastructure. Furthermore, the increasing cardiovascular rate along with the rising population inclined towards the sedentary lifestyle is driving the growth of the facial paralysis market. According to the European Heart Network, in 2015, there were 11.3 million cardiovascular disorder cases in Europe.
Asia Pacific is expected to be the fastest growing market owing to the increasing prevalence of cardiovascular disorders and increasing inflammation rates. China is the fastest growing region owing to an increasing population. The increasing awareness about the health and availability of new treatment methods drives the market in this region. Increasing healthcare expenditure and rise in the standard of living are driving the growth of the facial paralysis market in the Asia Pacific region.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness and limited access and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the development of the healthcare industry and increasing availability of specialty care centers.
Key Players
Some of the key players in the facial paralysis market are Boston Scientific, BioControl Medical, Cerebomed, Cyberonics, Astellas Pharma Inc., Sucampo Pharmaceuticals, Inc., and Novartis AG, among others.
Frequently Asked Questions (FAQ) :
Facial paralysis is a restriction of facial muscles due to nerve damage.
Global Facial Paralysis Market is expected to exhibit a strong 6.5% CAGR over the forecast period from 2018 to 2023.
The increasing rate of stroke is likely to be a major driver for the Facial Paralysis Market.
The Americas hold a dominant 48% share in the global Facial Paralysis Market.
Leading players in the Facial Paralysis Market include Boston Scientific, Cerebomed, and Astellas Pharma, among others.
Table of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6. Global Facial Paralysis Market, by Type
6.1 Introduction
6.2 Bell’s Palsy
6.2.1 Market Estimates & Forecast, 2018–2023
6.3 Ramsay Hunt Syndrome
6.3.1 Market Estimates & Forecast, 2018–2023
6.4 Lyme Disease
6.4.1 Market Estimates & Forecast, 2018–2023
7. Global Facial Paralysis Market, by Diagnosis
7.1 Introduction
7.2 Electromyography (EMG)
7.2.1 Market Estimates & Forecast, 2018–2023
7.3 Computerized Tomography (CT)
7.3.1 Market Estimates & Forecast, 2018–2023
7.4 Magnetic Resonance Imaging (MRI)
7.4.1 Market Estimates & Forecast, 2018–2023
8. Global Facial Paralysis Market, by Treatment
8.1 Introduction
8.2 Medications
8.2.1 Corticosteroids
8.2.2 Antiviral Drugs
8.2.3 Market Estimates & Forecast, 2018–2023
8.3 Physical Therapy
8.3.1 Market Estimates & Forecast, 2018–2023
8.4 Surgery
8.4.1 Market Estimates & Forecast, 2018–2023
9. Global Facial Paralysis Market, by End-User
9.1 Introduction
9.2 Hospitals
9.2.1 Market Estimates & Forecast, 2018–2023
9.3 Specialty Centers
9.3.1 Market Estimates & Forecast, 2018–2023
9.4 Research Centers
9.4.1 Market Estimates & Forecast, 2018–2023
10 Global Facial Paralysis Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K.
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
11 Company Profiles
11.1 BioControl Medical
11.1.1 Company Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 Boston Scientific
11.2.1 Company Overview
11.2.2 Product Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Sucampo Pharmaceuticals, Inc.
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Cerebomed
11.4.1 Company Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Cyberonics
11.5.1 Company Overview
11.5.2 Product Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.6 Astellas Pharma Inc.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.7 Novartis AG
11.7.1 Overview
11.7.2 Product Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Others
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of the Pharmaceutical Industry
13 Appendix
LIST OF TABLES
Table 1 Facial Paralysis Industry Synopsis, 2018–2023
Table 2 Global Facial Paralysis Market Estimates & Forecast, 2018–2023, (USD Million)
Table 3 Global Facial Paralysis Market, by Region, 2018–2023, (USD Million)
Table 5 Global Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 6 Global Facial Paralysis Market, by Diagnosis, 2018–2023, (USD Million)
Table 7 Global Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
Table 8 North America Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 9 North America Facial Paralysis Market, by Diagnosis, 2018–2023, (USD Million)
Table 10 North America Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
Table 11 U.S. Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 12 U.S. Facial Paralysis Market, by Diagnosis, 2018–2023, (USD Million)
Table 13 U.S. Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
Table 14 Canada Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 15 Canada Facial Paralysis Market, by Diagnosis, 2018–2023, (USD Million)
Table 16 Canada Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
Table 17 South America Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 18 South America Facial Paralysis Market, by Diagnosis, 2018–2023, (USD Million)
Table 19 South America Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
Table 20 Europe Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 21 Europe Facial Paralysis Market, by Diagnosis, 2018–2023, (USD Million)
Table 22 Europe Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
Table 23 Western Europe Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 24 Western Europe Facial Paralysis Market, by diagnosis, 2018–2023, (USD Million)
Table 25 Western Europe Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
Table 26 Eastern Europe Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 27 Eastern Europe Facial Paralysis Market, by diagnosis, 2018–2023, (USD Million)
Table 28 Eastern Europe Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
Table 29 Asia Pacific Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 30 Asia Pacific Facial Paralysis Market, by diagnosis, 2018–2023, (USD Million)
Table 31 Asia Pacific Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
Table 32 Middle East & Africa Facial Paralysis Market, by Treatment, 2018–2023, (USD Million)
Table 33 Middle East & Africa Facial Paralysis Market, by diagnoses, 2018–2023, (USD Million)
Table 34 Middle East & Africa Facial Paralysis Market, by End-User, 2018–2023, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Facial Paralysis Market
Figure 3 Segmentation Market Dynamics for Facial Paralysis Market
Figure 4 Global Facial Paralysis Market Share, by Treatment 2016
Figure 5 Global Facial Paralysis Market Share, by Diagnosis 2016
Figure 6 Global Facial Paralysis Market Share, by End-User, 2016
Figure 7 Global Facial Paralysis Market Share, by Region, 2016
Figure 8 North America Facial Paralysis Market Share, by Country, 2016
Figure 9 Europe Facial Paralysis Market Share, by Country, 2016
Figure 10 Asia Pacific Facial Paralysis Market Share, by Country, 2016
Figure 11 Middle East & Africa Facial Paralysis Market Share, by Country, 2016
Figure 12 Global Facial Paralysis Market: Company Share Analysis, 2016 (%)
Figure 13 Abbott Laboratories: Key Financials
Figure 14 Abbott Laboratories: Segmental Revenue
Figure 16 Abbott Laboratories: Geographical Revenue
Figure 17 Synergy Pharmaceuticals, Inc.: Key Financials
Figure 18 Synergy Pharmaceuticals, Inc.: Segmental Revenue
Figure 19 Synergy Pharmaceuticals, Inc.: Geographical Revenue
Figure 20 Sucampo Pharmaceuticals, Inc.: Key Financials
Figure 21 Sucampo Pharmaceuticals, Inc.: Segmental Revenue
Figure 22 Sucampo Pharmaceuticals, Inc.: Geographical Revenue
Figure 23 Novartis AG: Key Financials
Figure 24 Novartis AG: Segmental Revenue
Figure 25 Novartis AG: Geographical Revenue
Figure 26 GlaxoSmithKline plc: Key Financials
Figure 27 GlaxoSmithKline plc: Segmental Revenue
Figure 28 GlaxoSmithKline Plc. Geographical Revenue
Figure 29 Ardelyx, Inc.: Key Financials
Figure 30 Ardelyx, Inc.: Segmental Revenue
Figure 31 Ardelyx, Inc.: Geographical Revenue
Figure 32 Astellas Pharma Inc.: Key Financials
Figure 33 Astellas Pharma Inc.: Segmental Revenue
Figure 34 Astellas Pharma Inc.: Geographical Revenue
